Table 1 Characteristics, laboratory findings, and clinical outcomes of participants

Age, years^a

9.8 ± 2.4

Male, n (%)

31 (57.4%)

Treatment during a stable state, n (%)

 ICS

6 (11.1%)

 ICS/LABA

22 (40.7%)

 Anti-lgE antibody

1 (1.9%)

Symptom

 Wheezes, n (%)

46 (85.2%)

 Duration of URTI symptoms before consultation, days^b

3 (2–6)

Body temperature, °C^a

37.3 ± 0.8

Laboratory findings

 CRP, mg/dL^b

0.49 (0.11–1.15)

 WBC count, /μL^a

8453 ± 2763

 Eosinophil count in bloods, /μL^b

130 (11–537)

 Eosinophil percentage in blood, %^b

1.5 (0.1–6.3)

 Total serum IgE, IU/mL^b

1050 (595–1891)

Hospitalization duration, days^b

7 (6–8)

Treatment with systemic corticosteroids, n (%)

53 (98.1%)

Duration with systemic corticosteroids, days^b

5 (4–7)